7 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
, including a change to its internal clinical development indications and a related reduction of the Company’s workforce followed by certain
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
and auto-immune verticals, the Company intends to reduce its workforce by approximately 50%. The workforce reductions and the savings associated
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
workforce by approximately 50%. The workforce reductions and the savings associated with the reclassification of the oncology indications as candidates … to reduce its workforce by approximately 50%. The workforce reductions and the savings associated with the reclassification of the oncology indications
6-K
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
on the inflammatory and auto-immune verticals, the Company intends to reduce its workforce by approximately 50%. The workforce reductions and the savings
20-F/A
2018 FY
ENLV
Enlivex Therapeutics Ltd
23 Jan 20
Annual report (foreign) (amended)
4:31pm
, primarily as result of workforce reductions discussed in Note 13. As a result, $359, $144 and $1,424 of previously recognized share-based compensation
- Prev
- 1
- Next